Anne-Marie Heegaard, M.D., Ph.D. is Associate Professor at the Department of Drug Design & Pharmacology, University of Copenhagen. Anne-Marie Heegaard’s laboratory focuses on molecular and cellular mechanisms underlying malignant and non-malignant bone pain. Her research is translational and ranges from in vitro studies to animal models and clinical investigations. Previously Dr. Heegaard was Head of in vivo pharmacology at a biotech company. Dr. Heegaard is the coordinator for the European Training Network: BonePain
BSc, PhD, FmedSci., Professor, Group Leader
Dept. of Neuroscience, Physiology, & Pharmacology
Anthony Dickenson, BSc, PhD, FmedSci, FBPharmcolS is Professor of Neuropharmacology in the Department of Neuroscience, Physiology and Pharmacology at University College, London, UK. He has held posts in Paris, California and Sweden. His research interests are the pharmacology and mechanisms of pain and how to translate basic science to the patient. Prof. Dickenson is an Honorary Member of the British Pain Society. He has authored more than 300 refereed publications with an h index of 80, all due to his motivated and brilliant research team; he is a founding and continuing member of the Wellcome Trust funded London Pain Consortium.
PhD, DSc, FMedSci, FRS, Professor, Group Leader
Institute for Biomedical Research
John Wood’s laboratory focuses on peripheral drive as a key element in acute, inflammatory and neuropathic pain. He pioneered the identification of sensory neuron-enriched genes and exploited molecular genetics to examine deficits in pain behavior using transgenic knock-out mice. The first sensory neuron tissue-specific knock-out mice were generated by his team at UCL in 2004. This pioneering work led to the identification of many proteins that have a key role in pain, and by combining mouse and human genetics, have had major translational and clinical significance, as more than 1000 new chemical entities focused on analgesic targets identified by the Wood lab have been patented. The targets he identified and validated in transgenic mice, such as Nav1.8, P2X3 and Nav1.7 are now all major areas of activity by pharmaceutical companies developing new classes of analgesic drugs.
PhD, HDR, Reader, Group Leader
Department of Comparative Biomedical Sciences
Chantal Chenu is a Reader in Bone Cell Biology at the Royal Veterinary College in London. After graduating from the University of Lyon with a degree in Biochemistry, she conducted her PhD research in David Roodman‘s laboratory in San Antonio, Texas on osteoclast differentiation. She then joined Pierre Delmas’ group in Lyon, where she became an independent INSERM researcher focusing her research on the role of the nervous system in the control of bone mass. She moved to London in 2003 and her more recent research interests are the regulatory and repair mechanisms of bone. Chantal Chenu is a member of the Editorial board of J of Endocrinology and J of Molecular Endocrinology.
Dr. Camilla Svensson received her Ph.D in Molecular Pathology from University of California, San Diego in 2005 and then undertook post-doctoral work centered on inhibitory regulation of intracellular signaling in rheumatoid arthritis at the same university. Dr. Svensson started her laboratory at the Karolinska Institutet, Department of Physiology and Pharmacology, in 2008, where she today is an Assistant Professor and Wallenberg Academy Fellow and Söderberg Fellow in Medicine. She is leading a research team exploring pain mechanisms in rheumatic disease, with a specific focus the role of antibodies and glial cells in pain processing.
PhD, Assistant Professor
Laboratory of Neuroimmunology and Developmental Origins of Disease
Dr. Niels Eijkelkamp graduated in 2003 at the Utrecht University and received his PhD in 2009 on mechanism of inflammatory pain. His first postdoctoral positions he had a joint-appointment at the University of Illinois at Urbana-Champaign, USA and University Medical Center Utrecht centering his work on neuroimmune regulation of pain. Starting in 2010 he performed postdoctoral research funded by fellowship for 2 years at laboratory of Prof Wood at the University College London where his worked focussed the molecular basis of mechanotransduction, touch and allodynia. In 2012 he started his group at the University Medical Center Utrecht that is geared at unravelling mechanism of inflammatory pain, with a focus on neuroimmune interactions, involvement of the peripheral immune system and identification of novel chronic pain targets.
Dr. Kris Rutten has 12 years of experience in behavioral pharmacology over a broad range of indications (pain, cognition, anxiety, depression, addiction). He received his Ph.D. in 2007 from Maastricht University on phosphodiesterase inhibitors in learning and memory and held a post-doc position during which he was appointed visiting researcher at Roche Pharmaceuticals in Palo Alto, USA. Starting 2008 he has served as post-doc and laboratory head at the pharmacology department of Grünenthal GmbH in Aachen, focusing his research on discovery of chronic pain and inflammation treatments. Specifically, his group focuses on new readouts of non-evoked pain and assessment of PK/PD relationships.
Kim Henriksen, M.Sc., PhD has during the last ten years focused his research on drug discovery and development of novel biomarkers within the fields of osteoporosis and diabetes.The pharmacological work has resulted in the development of a large pharmacological program for the identification of inhibitors of the chloride channel ClC-7 to be used for treatment of osteoporosis and osteoarthritis. In addition, he leads a pharmacological program focused on the development of a dual acting calcitonin and amylin receptor agonist as a treatment for type 2 diabetes. The efforts have resulted in more than 100 publications in peer-reviewed journals.
Amy Fisher, BSc, PhD is the Principal Scientist in pain research at Transpharmation Ltd., London, UK. She is a professional researcher with a strong scientific background in neuropharmacology, pharmacology and the physiology of pain processing. She has held a variety of posts enabling development of strong collaborative links within both academia and industry. She is an expert in preclinical neuropathic and inflammatory pain models and their role in drug discovery and novel target validation. Her research interests include developing translatable measurements in naturally occurring/spontaneous pain models along with identifying biomarkers of responders/non-responders to gold-standard treatments using a novel transcriptomic approach.
Thomas Levin Andersen, MSc, PhD is an Associate Professor at the Department of Clinical Cell Biology at Vejle Hospital, which is a focused bone research group under the Institute of Regional Health Research, University of Southern Denmark. Thomas Levin Andersen has 15 years of experience in bone research. Thomas Levin Andersen’s research focuses mainly on the supracellular organization of the human bone remodeling under physiological and pathophysiological conditions, and especially the players involved in the coupling of bone formation to resorption.